会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 악성 미분화 종양줄기세포 표적 펩타이드
    • 胶原蛋白结合不全的玻璃体细胞
    • KR1020120099904A
    • 2012-09-12
    • KR1020110018414
    • 2011-03-02
    • 서울대학교산학협력단
    • 최윤재김형기백삼열강상기이남경김훈
    • C07K7/06G01N33/68A61K38/08A61P35/00
    • C07K7/06A61K38/08A61K47/66G01N33/57407
    • PURPOSE: A malignant undifferentiated cancer stem cell target peptide is provided to effectively and accurately deliver anti-cancer drug to tumor cells by targeting nestin-positive cells of tumor cells. CONSTITUTION: A malignant undifferentiated cancer stem cell target peptide GICT has AQYLNPS sequence which can selectively recognizes and combines with the malignant undifferentiated tumor stem cells. A marker for diagnosing malignant cancers uses the cancer stem cell target peptide GICT having AQYLNPS sequence. A method for screening the cancer stem cell target peptide, which can selectively recognize and combine with the malignant undifferentiated cancer stem cells, uses phage display technique. The method for sorting and inspecting the cancer stem cell target peptide comprises the following steps: prying the cancer stem cell target peptides through sorting the cancer stem cell bonded phage and analyzing the individual phage combination aspect by using the page display technique; analyzing combining ability of the pried cancer stem cell target peptide with the various cells; sorting and verifying the protein bonded with the pried cancer stem cell target peptide; verifying the cancer tissue transmission ability of the cancer stem cell target peptide in a cancer model mouse; verifying undifferentiated cancer stem cell specific targeting ability of the cancer stem cell target peptide in the brain tumor organization; and confirming the cancer cell growth inhibition ability in the tumor model mouse of the tumor stem cell target peptide.
    • 目的:通过靶向肿瘤细胞的巢蛋白阳性细胞,提供恶性未分化癌症干细胞靶肽,以有效和准确地将抗癌药物递送至肿瘤细胞。 构成:恶性未分化癌症干细胞靶肽GICT具有AQYLNPS序列,可以选择性识别和与恶性未分化肿瘤干细胞结合。 用于诊断恶性肿瘤的标记物使用具有AQYLNPS序列的癌干细胞靶肽GICT。 筛选可以选择性识别和与恶性未分化癌细胞结合的癌干细胞靶肽的方法,使用噬菌体展示技术。 癌症干细胞靶肽分选检测方法包括以下步骤:通过分选癌干细胞粘附的噬菌体,通过使用页面显示技术分析单个噬菌体组合方面,来窥探癌症干细胞靶肽; 分析pri癌干细胞靶肽与各种细胞的结合能力; 分选和验证与脯氨酸癌干细胞靶肽结合的蛋白质; 验证癌症模型小鼠中癌干细胞靶肽的癌组织传播能力; 验证癌症干细胞靶肽在脑肿瘤组织中的未分化癌干细胞特异性靶向能力; 并确认肿瘤干细胞靶肽的肿瘤模型小鼠中的癌细胞生长抑制能力。
    • 4. 发明公开
    • 모공을 통해 피부를 투과하는 경피 전달용 펩타이드
    • 穿透皮肤上的头发皮肤的转移性皮肤
    • KR1020120104036A
    • 2012-09-20
    • KR1020110022096
    • 2011-03-11
    • 서울대학교산학협력단
    • 최윤재이남경강상기백삼열
    • C07K7/06A61K38/08A61K47/42
    • Y02A50/473C07K7/06A61K47/62
    • PURPOSE: A transdermal peptide is provided to promote body delivery of large drug molecules. CONSTITUTION: A pore penetration peptide is SSHTISF, FPQPPQR, AFTPAKT or SPWIPAV. The transdermal peptide is SSHTISF, FPQPPQR, AFTPAKT or SPWIPAV. The SSHTISF peptide is ST1 peptide(Ser-Ser-His-Thr-Ile-Ser-Phe). The FPQPPQR peptide is ST2 peptide(Phe-Pro-Gln-Pro-Pro-Gln-Arg). The AFTPAKT peptide is ST2 peptide(Ala-Phe-Thr-Pro-Ala-Lys- Thr). The SPWIPAV peptide is ST4 peptide(Ser-Pro-Trp-Ile-Pro-Ala-Val). [Reference numerals] (AA) Repeat of biopanning round(1-3 times); (BB) Random transdermal administration of phage-peptide library into rat; (CC) Blood collection through heart at predetermined time after administration to collect skin penetrating phage; (DD) Amplificatioin of phage mixture collected from E.coli ER2738; (EE) Selecting each recombinant phage from biopanning of third round and determining peptide-coding nucleotide sequence; (FF) Peptide sequence identification from nucleotide sequence
    • 目的:提供透皮肽以促进大量药物分子的体内递送。 构成:孔渗透肽是SSHTISF,FPQPPQR,AFTPAKT或SPWIPAV。 透皮肽是SSHTISF,FPQPPQR,AFTPAKT或SPWIPAV。 SSHTISF肽是ST1肽(Ser-Ser-His-Thr-Ile-Ser-Phe)。 FPQPPQR肽是ST2肽(Phe-Pro-Gln-Pro-Pro-Gln-Arg)。 AFTPAKT肽是ST2肽(Ala-Phe-Thr-Pro-Ala-Lys-Thr)。 SPWIPAV肽是ST4肽(Ser-Pro-Trp-Ile-Pro-Ala-Val)。 (附图标记)(AA)生物平扫重复(1-3次); (BB)将噬菌体肽文库随机透皮给药至大鼠; (CC)在给药后的预定时间通过心脏采集皮肤渗透性噬菌体; (DD)从大肠杆菌ER2738收集的噬菌体混合物的扩增; (EE)从第三轮的生物淘选中选择每个重组噬菌体并确定肽编码的核苷酸序列; (FF)核苷酸序列的肽序列鉴定